CDMO

Pharmaceutical Development & Manufacturing
Online Inquiry
Verification code

Cell Therapy Product Development

We provide end-to-end laboratory programs within Pharmaceutical Development & Manufacturing and its child service Drug Substance Development. Our team advances cell-based modalities from early feasibility into robust, well-characterized drug-substance processes, emphasizing quality-by-design, analytical depth, and documentation that supports seamless progression to later lifecycle stages.

Overview of Cell Therapy Product Development

Cell therapy product development integrates cell-source qualification, engineered construct verification (where relevant), process definition across unit operations, and a comprehensive analytical control strategy. Autologous programs prioritize highly controlled workflows for heterogeneous, small-volume starting materials; allogeneic programs emphasize clonality, bank strategy, and lot-to-lot reproducibility.

Our Services

Our CDMO portfolio centers on drug substance development within a pharmaceutical framework. We offer autologous cell therapy product development and allogeneic cell therapy product development services. Each service is operated as a focused, laboratory-based workstream with clear deliverables—development reports, methods, and data packages suitable for downstream manufacturing enablement.

Autologous Cell Therapy Product Development

We deliver autologous-specific, laboratory-focused CMC solutions encompassing strategic planning, process development, analytical characterization, and comprehensive technical documentation. Our approach is tailored to the unique challenges of same-source cell therapies, enabling the transformation of patient- or donor-derived starting materials into consistent, well-controlled, and well-characterized drug substances.

Allogeneic Cell Therapy Product Development

We deliver a laboratory-centric, CDMO pathway for allogeneic cell drug substances: qualified sources and banks, precise engineering control, and rigorous analytics. Our services transform allogeneic cell concepts into robust, well-characterized drug substances engineered for consistency, safety, and scale.

We deliver laboratory-anchored CDMO programs for autologous and allogeneic cell-therapy drug substances, uniting process engineering, analytics, and stability. Our teams convert promising concepts into reproducible, well-controlled processes. Contact us to scope data-driven development tailored to your modality.

Frequently Asked Questions

Q1: How is potency quantified when mechanisms are multifactorial?

We employ orthogonal assays: a primary functional surrogate (e.g., co-culture activation or cytotoxic readout), a secondary biomarker or reporter assay, and a structural/phenotypic correlate. Results are integrated via predefined algorithms, with reference-standard management and system suitability to maintain assay continuity.

Our products and services are for research use only.

Inquiry

For any inquiry, question or recommendation, please fill out the following form.

Verification code
Online Inquiry
HEADQUARTERS

Tel:

Fax:

Email:

QUICK LINKS

Research

Development

GMP Manufacturing

Services

About Us

FOLLOW US

Privacy Policy | Cookie Policy | Copyright © 2026 . All rights reserved.

TOP